Real-world analysis of teclistamab in 123 RRMM patients from Germany
Most Cited Paper
in Monoclonal and Polyclonal Antibodies Research
18 Months Post-Publication
Class of 2026
“Real-world analysis of teclistamab in 123 RRMM patients from Germany”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/
Topics
teclistamab · BCMA-CD3 bispecific antibody · MajesTEC-1 · Relapsed/refractory multiple myeloma · Triple-class refractory multiple myeloma · Penta-drug refractory multiple myeloma · prior BCMA-directed therapy · idecabtagene vicleucel · CAR T-cell therapy · Objective response rate · Progression-free survival · Extramedullary disease · ISS stage III · Duration of response · BCMA-naive patients · cytopenias · infections as adverse events · Real-world evidence · German multicenter cohort · Retrospective analysis
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459